Form 4: Humacyte Director Emery Brown Granted 80,000 Stock Options

Humacyte, Inc. Director Emery N. Brown was granted 80,000 stock options with an exercise price of $2.41, vesting over four years.

Summary

• Emery N. Brown, a Director of Humacyte, Inc. (HUMA), was granted 80,000 stock options.
• The transaction date for this grant was June 12, 2025.
• The exercise price for these options is $2.41 per share.
• The options have an expiration date of June 12, 2035.
• The vesting schedule dictates that the first 25% of the options become exercisable on June 12, 2026.
• Following the initial vesting, 1/48th of the option will become exercisable on the 12th of each month through June 12, 2029.
• After this transaction, Emery N. Brown beneficially owns 80,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive as it indicates alignment of director's interests with shareholders through equity compensation, which is a standard and generally favorable practice. No negative operational or financial news is present.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Negatives

• The grant of new options could lead to potential future dilution if exercised, although this is a standard component of equity compensation.

Risks

• No specific risks are detailed in this Form 4 filing, as it primarily reports an insider transaction.

Future Outlook

The vesting schedule for the granted stock options extends through June 12, 2029, indicating a long-term incentive structure for the director.

Management Comments

• "Emery N. Brown by Dale A.Sander as Attorney-in-Fact" (signature line, indicating the transaction was reported on behalf of the director).

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and healthcare industry, serving as a key component of executive and board compensation packages designed to align leadership interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of 80,000 stock options to a director is a standard form of equity compensation, comparable to practices at other small to mid-cap biotechnology companies like Organogenesis Holdings Inc. (ORGO) or MiMedx Group, Inc. (MDXG), which also utilize stock options and restricted stock units to incentivize their board members.
• The 10-year expiration period for the options is typical for long-term incentive plans across the industry, similar to option grants observed at companies such as Veru Inc. (VERU) or Athersys, Inc. (ATHX).
• The four-year vesting schedule (25% after one year, then monthly) is a common structure designed to ensure continued service and performance, mirroring vesting patterns seen in compensation plans at companies like BioLife Solutions, Inc. (BLFS).

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also increased alignment of director's interests with shareholder value creation.
• Director (Emery N. Brown): Receives long-term equity incentive compensation tied to the company's stock performance.

Next Steps

• The options will begin to vest on June 12, 2026, with 25% becoming exercisable.
• Subsequent vesting will occur monthly (1/48th) through June 12, 2029.
• The director may choose to exercise the options at any point after they vest and before their expiration on June 12, 2035.

Key Dates

Keywords

Humacyte, HUMA, Emery N. Brown, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule